Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in South Korea / NCT07198191
Active, not recruiting Observational

SGLT2 Inhibitor Use After Acute Myocardial Infarction in Patients With Type 2 Diabetes: A Nationwide Cohort Study

NCT07198191 · tracked via the Priya Life Science South Korea tracker
Sponsor
Yonsei University
Phase
Observational
Started
2014-09-01
Last updated
2025-09-30

Condition(s) studied

Acute Myocardial Infarction (AMI)Type 2 Diabetes Mellitus (T2DM)

Investigational drug(s) / intervention(s)

SGLT2 inhibitors (e.g., dapagliflozin, empagliflozin)DPP4 inhibitors

SGLT2 inhibitors (e.g., dapagliflozin, empagliflozin): Exposure to SGLT2 inhibitors following AMI in patients with T2DM

DPP4 inhibitors: Exposure to DPP4 inhibitors following AMI in patients with T2DM

Study summary

This observational, retrospective cohort study aims to evaluate the impact of sodium-glucose cotransporter 2 (SGLT2) inhibitor use after acute myocardial infarction (AMI) in patients with type 2 diabetes mellitus (T2DM). Using the nationwide database from the Korean National Health Insurance Service, the investigators will compare cardiovascular outcomes between patients treated with SGLT2 inhibitors and those treated with dipeptidyl peptidase-4 (DPP4) inhibitors after AMI. The study period includes patients diagnosed with AMI between September 2014 and June 2021, with follow-up data available through June 2022. The primary outcomes include major cardiovascular events (death, myocardial infarction, stroke) and bleeding events. This study will provide real-world evidence on the effectiveness and safety of SGLT2 inhibitors in routine clinical practice following AMI among patients with T2DM in Korea.

Eligibility

Sex
ALL
Min age
19 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Adults aged ≥19 years * Hospitalization with a primary diagnosis of acute myocardial infarction between September 2014 and June 2021 * Diagnosis of type 2 diabetes mellitus (T2DM) * Prescription of either an SGLT2 inhibitor or a DPP4 inhibitor after index AMI Exclusion Criteria: * Diagnosis of type 1 diabetes mellitus * Gestational diabetes mellitus * End-stage renal disease (ESRD) or history of kidney transplantation * No use of either SGLT2 inhibitor or DPP4 inhibitor after index AMI * Short-term use of SGLT2 inhibitor or DPP4 inhibitor (less than 30 days) * Concomitant use of SGLT2 inhibitor and DPP4 inhibitor * Incomplete or missing data for key study variables

Primary outcome measure(s)

  • Incidence of Major Adverse Cardiovascular Events (MACE) — From index date (hospitalization for AMI), upto 365 days
    MACE defined as a composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal ischemic stroke.

Trial sites (1)

FacilityCityRegionStatus
Yongin Severance Hospital, Yonsei University Health System Yongin Gyeonggi-do

More Yonsei University trials in South Korea

Window of Opportunity Trial of Durvalumab (MEDI4736) to Identify Immune Dynamics in Operable Non-small Cell Lung Cancer (NSCLC) (MIRACLE) Active, not recruiting
Long-term Outcomes After Percutaneous Patent Foramen Ovale Closure (Severance PFO Registry) Recruiting
Outcome in Patients Treated With Endovascular Thrombectomy - optIMAL Blood Pressure Control 2 (OPTIMAL-BP 2) Recruiting
Economic and Clinical Benefit of Remote Monitoring Among Defibrillator Patients by Indication Subgroups (BENEFIT-RM) Recruiting
The Effects of Virtual Reality-based Training for the Treatment of Neglect Syndrome in Stroke: a Randomized Controlled Trial Recruiting

Other trials for the same condition

A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM) Active, not recruiting
Cardioprotective Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Korean Patients With Type 2 Diabetes Starting soon
Routine Use of Potassium Competitive Acid Blocker vs. Guideline-Directed Gastrointestinal Protection Strategy in Acute Myocardial Infarction Recruiting
Cilostazol and Aspirin for Cardiovascular Event Prevention in Patients With Type 2 Diabetes Recruiting
ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07198191 on ClinicalTrials.gov ↗ ← All trials in South Korea